Amarin’s loss of a crucial patent lawsuit shows that potential buyers were right to be wary of the Vascepa opportunity.
Though the stage is apparently set for Bristol’s contingent value right to pay out, the instrument trades at depressed levels.
A US patent victory could give Amgen’s Enbrel another eight years’ patent exclusivity, but is the enthusiasm justified?
The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
Generic versions of Acorda’s Ampyra are about to flood the market, meaning that the company desperately needs a timely approval in October for its next big hope.
Unitary patents are important for the biopharma sector, but might be even more crucial for medtech.
Generic versions of Glaxosmithkline's Advair have been delayed again, but doubts about the group's HIV doublets are creeping in.
Biogen might be wondering what else it could have spent $1.2bn on as Forward Pharma's patent challenge against Tecfidera falters.